Frankfurt
24.04.25
08:05 Uhr
0,062 Euro
-0,001
-1,89 %
-1,89 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,093 | 0,098 | 24.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update | 211 | Business Wire | Commercial activities remain strong, including CellTolerance launch Recently approved safeguard proceeding yielding productive creditor and investor discussions aimed at strengthening Mauna Kea's... ► Artikel lesen | |
| 07.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 148 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF Listing: Euronext Growth Paris
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing:... ► Artikel lesen | |
| 01.04. | Mauna Kea Technologies Announces Entrance Into Exclusive Negotiations for a Licensing Agreement for Cellvizio in an Important Therapeutic Area With a Major Industry Player | 270 | Business Wire | The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify... ► Artikel lesen | |
| 31.03. | Mauna Kea Technologies Announces the Opening of a Safeguard Proceeding to Restructure Its Financial Liabilities | 490 | Business Wire | The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The procedure will also provide a protective framework favorable... ► Artikel lesen | |
| 06.03. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 237 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.03. | Mauna Kea Technologies: Cellvizio Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis | 246 | Business Wire | ESGE, Europe's leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step towards broader commercial adoption
Regulatory... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 247 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 27.01. | Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio for Precision Surgery in Head and Neck Cancers | 341 | Business Wire | Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx, oropharynx and hypopharynx Cellvizio helped identify... ► Artikel lesen | |
| 21.01. | Mauna Kea Technologies: Half-Year Liquidity Contract Statement for H2 2024 With the Brokerage Firm Gilbert Dupont | 633 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen | |
| 20.01. | Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex | 349 | Business Wire | 13th U.S. AI patent awarded to Mauna Kea Expanded patent portfolio boosts platform value, supports strategic partnerships
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT)... ► Artikel lesen | |
| 15.01. | Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update | 419 | Business Wire | Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks RM Global and Bucephale Finance mandated to... ► Artikel lesen | |
| 14.01. | Mauna Kea Technologies Announces Its 2025 Financial Calendar | 260 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®,the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces... ► Artikel lesen | |
| 09.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 424 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.12.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 385 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.11.24 | Mauna Kea Technologies: Raising Pancreatic Cancer Awareness Through Patient Voices | 182 | Business Wire | With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer
Regulatory News:
This Pancreatic Cancer Awareness Month... ► Artikel lesen | |
| 20.11.24 | Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador | 128 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased... ► Artikel lesen | |
| 13.11.24 | Mauna Kea Technologies Provides an Update on Its Recent Developments | 357 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides... ► Artikel lesen | |
| 06.11.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 333 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website:... ► Artikel lesen | |
| 17.10.24 | Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance | 431 | Business Wire | Major New Study Presented at the World's Largest Gastroenterology Congress Validation of Mauna Kea's Growth Strategy with CellTolerance® in a $6 Billion a Year Market Opportunity
Regulatory... ► Artikel lesen | |
| 15.10.24 | Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales | 422 | Business Wire | Confirmation of lower breakeven point trajectory with 9% Reduction in Operational Expenses Q3 2024 Sales Growth of +24%1 Driven by New System Sales in the U.S. and Europe Official Launch of... ► Artikel lesen |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,133 | +0,76 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
| FAMICORD | 4,200 | +3,45 % | EQS-AFR: FamiCord AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: FamiCord AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
FamiCord AG: Vorabbekanntmachung über die Veröffentlichung... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,860 | +2,88 % | Geratherm Medical Aktie: Ruhige Zeiten angekündigt? | Das Medizintechnikunternehmen passt Produktionskapazitäten für klinische Thermometer bei fortgesetzter Marktschwäche an, während die Aktie trotz Volatilität zuletzt zulegte. Die Geratherm Medical AG... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,880 | 0,00 % | Plus Therapeutics beruft Kyle Guse in den Vorstand | ||
| ATOSSA THERAPEUTICS | 0,639 | -0,93 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast... ► Artikel lesen | |
| MEDICLIN | 2,920 | -2,01 % | EQS-HV: MEDICLIN Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 04.06.2025 in Bad Neustadt a. d. Saale mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: MEDICLIN Aktiengesellschaft
/ Bekanntmachung der Einberufung zur Hauptversammlung
MEDICLIN Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,065 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain | BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-Q, Quarterly Report | ||
| VERU | 0,468 | -3,70 % | Veru Aktie: Bedeutet das eine Neuausrichtung? | Die Veru-Aktie verliert weiter an Wert, doch Analysten bleiben optimistisch aufgrund vielversprechender Medikamentenentwicklungen. Wird der Tiefpunkt bald erreicht? Die Veru-Aktie setzt ihre Abwärtsspirale... ► Artikel lesen | |
| LIFEWARD | 1,480 | 0,00 % | Lifeward Ltd.: FDA Issues Clearance for ReWalk 7 Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| LIGHT AI | 0,329 | +1,23 % | Light AI Inc.: Light AI Appoints George Reznik CFO and Corporate Secretary | VANCOUVER, BC, Jan. 27, 2025 /CNW/ - Light AI Inc. (CBOE: ALGO) ("Light AI" or the "Company"), a global healthcare technology company focused on developing artificial... ► Artikel lesen | |
| EKSO BIONICS | 0,360 | -4,76 % | Ekso Bionics Holdings, Inc.: Bionic P&O Chosen as First Distributor of Ekso Indego Personal Within the Orthotics & Prosthetics Industry | ||
| FRESENIUS | 39,850 | +0,94 % | BARCLAYS stuft Fresenius SE auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Fresenius von 44,00 auf 43,50 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. Die Bad Homburger dürften... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 45,880 | +0,55 % | EQS-DD: Siemens Healthineers AG: Darleen Caron, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
22.04.2025 / 17:45... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,001 (-1,89 %) liegt der Kurs bei 0,062 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.
